Market Place
Sourcing Support
All News #Library
Biotech
Galmed Collaborates With Tel Aviv University To Assess Aramchol
14 Apr 2026 //
PR NEWSWIRE
Galmed Unveils Brain-Penetrating Aramchol SCD1 Inhibitor
09 Apr 2026 //
PR NEWSWIRE
Galmed Pharma Files 2025 Annual Report on Form 20-F
01 Apr 2026 //
PR NEWSWIRE
Galmed`s Late-Breaking Abstract Accepted at HEP-DART Meeting
08 Dec 2025 //
PR NEWSWIRE
Galmed Secures Patents for Aramchol, Rezdiffra
04 Dec 2025 //
PR NEWSWIRE
Galmed Reports Significant AM-001 Study Results For Aramchol
18 Nov 2025 //
PR NEWSWIRE
Galmed Announces Top-line Results in Oncology MoA Studies
17 Nov 2025 //
PR NEWSWIRE
Galmed Pharmaceuticals Unveils Q2 2025 Financials and Business
28 Aug 2025 //
PR NEWSWIRE
Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models
13 May 2025 //
PR NEWSWIRE
Galmed sign Term Sheet for Novel Semaglutide sublingual formulation
28 Apr 2025 //
PR NEWSWIRE
Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer
17 Apr 2025 //
PR NEWSWIRE
Galmed`s Part 1 Results from AM-001 Study of Aramchol Meglumine
10 Apr 2025 //
PR NEWSWIRE
Galmed Pharmaceuticals Extends Aramchol Patent Protection to 2039
20 Mar 2025 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.